Abstract:Soft-Tissue Sarcomas (STS) are mesenchymal malignancies with high heterogeneity and poor prognosis. As recently shown, ABT-199 and Bortezomib (BTZ) synergistically induce apoptosis in STS derived cells and cell lines (Muenchow et al. 2020). This is of great importance due to limited clinical therapeutic options and lower dependence on BCL-2 expression in solid cancers. To delineate the molecular basis for the synergism of ABT-199 and BTZ, we thought to elucidate the mechanism leading to enhanced expression of the BH3-only protein NOXA. We investigated whether proteasome inhibition augmented the expression of NOXA in a TP53-regulated manner. To clarify a possible role of TP53 in increased NOXA expression, we performed knock-down of TP53 and analyzed transcription of PMAIP1 by qRT-PCR and expression of NOXA protein by Western Blot in presence of ABT-199 alone and in combination with BTZ. Previous reports also show that ABT-199 impairs complex I and II activity of the electron transport chain (ETC), resulting in induction of metabolic reprogramming confirmed by enhanced reductive carboxylation (Roca-Portoles et al. 2020). The ratio of α-ketoglutarate : citrate, indicating disbalance of the ETC, was assessed by mass spectrometric analysis in SW982/WT cells after incubation with ABT-199 alone and in combination with BTZ. Moreover, we gained further insight into the molecular mechanism of action of enhanced NOXA expression by analyzing ABT-199 and BTZ induced cell death induction in time kinetics of cell death induction in knock-down experiments using CellTOX Green as indicator. We found that ABT-199 induced the expression of NOXA by a mainly TP53-independent mechanism at the transcriptional level. Indeed, our data suggest that ABT-199 induces metabolic reprogramming leading to enhanced reductive carboxylation, evidenced by an increased ratio of α-ketoglutarate : citrate. Subsequent activation of the integrated stress response (ISR) induces expression of the known ISR markers ATF3 and ATF4 at both the transcriptional and protein levels. Silencing of ATF3 and ATF4 significantly reduced NOXA expression and NOXA mediated cell death induction. Therefore, we propose that transactivation of NOXA by ABT-199 and subsequent sensitization to proteasome inhibitors effectively induces cell death in solid cancers. The double impact of ABT-199 by i) directly blocking anti-apoptotic BCL-2 and ii) inhibiting MCL-1 via transactivated NOXA is of high clinical relevance, because combined treatment with proteasome inhibitors might overcome intrinsic or acquired resistance to BH3-mimetics. Thus, the here described novel effect of ABT-199 to transactivate NOXA expression, should prompt future efforts in the clinical evaluation of combinatorial regimens in additional malignancies. We hypothesize that these effects represent generally active principles of a tumor-agnostic mechanism of action. Citation Format: Sandra Weller, Benjamin Schaefer, Tobias B. Beigl, Kathrin Böpple, Ute Hofmann, Walter E. Aulitzky, Hans-Georg Kopp, Frank Essmann. Double impact of ABT-199 by directly blocking anti-apoptotic BCL-2 and inhibiting MCL-1 via transactivation of NOXA [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 3706.

MLN2238 Synergizes BH3 Mimetic ABT-263 in Castration-Resistant Prostate Cancer Cells by Induction of NOXA

AKT Inhibitor MK-2206 Sensitizes Breast Cancer Cells to MLN4924, a First-in-class NEDD8-activating Enzyme (NAE) Inhibitor

Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis

Targeted Inhibition of Mtor by BML-275 Induces Mitochondrial-Mediated Apoptosis and Autophagy in Prostate Cancer.

Bortezomib Potentiates Antitumor Activity of Mitoxantrone Through Dampening Wnt/β-catenin Signal Pathway in Prostate Cancer Cells

BH3 Mimetic ABT-737 Sensitizes Colorectal Cancer Cells to Ixazomib Through MCL-1 Downregulation and Autophagy Inhibition.

Androgen deprivation-induced senescence confers sensitivity to a senolytic strategy in prostate cancer

Magnetic Nanoparticle Of Fe3o4 And 5-Bromotetrandrin Interact Synergistically To Induce Apoptosis By Daunorubicin In Leukemia Cells

Abstract 2260: Novel Molecular Therapy Targeting Mcl-1 and Modulating Autophagy in Castration-Resistant Prostate Cancer

Abstract 956: NCX 4040 and napabucasin synergistically inhibits stemness in human prostate cancer (PCa) cellular models and potently targets transgenic murine PCa cells via inducing oxidative stress

Preclinical Development Synergistic Antitumor Activity of Gemcitabine and ABT-737 In Vitro and In Vivo through Disrupting the Interaction of USP 9 X and Mcl-1

Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration‐resistant prostate cancer cells to enzalutamide

Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer.

ML216-Induced BLM Helicase Inhibition Sensitizes PCa Cells to the DNA-Crosslinking Agent Cisplatin

Abstract 3706: Double impact of ABT-199 by directly blocking anti-apoptotic BCL-2 and inhibiting MCL-1 via transactivation of NOXA

The BET-Bromodomain Inhibitor JQ1 synergized ABT-263 against colorectal cancer cells through suppressing c-Myc-induced miR-1271-5p expression.

Nodularin‐R Synergistically Enhances Abiraterone Against Castrate‐ Resistant Prostate Cancer via PPP1CA Inhibition

Pretargeted radiotherapy and synergistic treatment of metastatic, castration-resistant prostate cancer using cross-linked, PSMA-targeted lipoic acid nanoparticles

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA

Synergistic effects of bloom helicase (BLM) inhibitor AO/854 with cisplatin in prostate cancer

Combination of navitoclax (Bcl-2 and Bcl-xL inhibitor) and Debio-0932 (Hsp90 inhibitor) suppresses the viability of prostate cancer cells via induction of apoptotic signaling pathway